Economia
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to (CTO), effective immediately.
Dr. Steiner will be responsible for manufacturing and process development for Transgene's innovative immunotherapy product pipeline. She will further lead the optimization of the manufacturing process for individualized neoantigen therapeutic vaccines. Simone Steiner will also be involved in the development of potential new candidates based on the platform, and in a second clinical study planned to start in Q4 2025.
Dr. Steiner reports to Chairman and CEO, Alessandro Riva, and is a member of the Executive Committee.
, commented: myvac
Simone Steiner, PhD, has almost 20 years of pharma experience across preclinical, clinical and commercialization gained within organizations ranging from startups to multinational Pharma companies.
Prior to joining Transgene, she was the Chief Technical Operating Officer (CTOO) at T-knife Therapeutics, a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, where she led technical development and manufacturing.
Before her time at T-knife, Dr. Steiner was Head of Technical Development and Manufacturing at Tigen, in Switzerland, where she managed the optimization of manufacturing processes and the creation of new biopharmaceutical products.
Dr. Steiner's career also includes over ten years at Novartis, where she expanded her expertise in technical operations and manufacturing, contributing to large-scale production strategies for groundbreaking therapies.
With a strong foundation in cutting-edge technologies and their implications for health, Dr. Steiner is recognized for combining scientific precision with strategic management to advance therapeutic development and manufacturing initiatives.
She served as a Scientific Advisor at NegotiumAI, an innovative platform leveraging state-of-the-art AI to streamline the relationship between advanced therapy drug developers and contract manufacturers.
Dr. Steiner holds a Master's in Biochemistry, a PhD from ETH Zurich and completed a postdoctoral fellowship at the University of Alberta, Canada.
***
myvac®
myvac® myvac
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene's website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-loo
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti